Biopharmaceutical Product Attributes and Biological Consequences Community

Please join this Open Scientific Discussion Panel Discussion hosted by the AAPS Biopharmaceutical Product Attributes and Biological Consequences (BPABC) Community on Tuesday, October 15 2024, 12 PM – 1 PM US EDT on:  

Connecting physicochemical properties of LNPs to in vivo behavior

Moderators:

Michael Zaleski, Senior Scientist, Merck & Co., Inc.

Panelists:

·         Ine Lentacker, Senior Researcher, Univ. of Ghent

·         Tom Anchordoquy, Professor, Univ. or Colorado, Anshutz

·         Miffy Cheng, Assistant Professor, Univ. of British Columbia

·         Jacob Brenner, Assistant Professor, Univ. of Pennsylvania

Discussion topics: 

1. What in vivo consequences of LNPs need to be considered (in addition to transfection efficiency / protein production)?
2. What is the status of in vitro-in vivo correlation for LNPs? Are any methods good predictors of specific in vivo behaviors? Are any in vitro methods misleading?
3. What ultimately prevents successful LNP therapies?
4. How effective are current targeting methods? Are any targeting methods misrepresented by the field?

We look forward to your participation in a lively discussion on this topic!

Please join Teams meeting using information provided below:

·         Meeting ID: 320 397 102 636

·         Password: Jsh3GC

Please feel free to share meeting information with your colleagues who may be interested in this discussion.

Thank you,

BPABC Leadership Team

------------------------------
Michael Zaleski
PhD Candidate
University of Pennsylvania
Philadelphia PA
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------